Should I Buy IMNN? IMNN 2026 Analysis

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.110

1 Day change

0.65%

52 Week Range

41.220

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

IMNN is not a good buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of trading signals, and neutral sentiment from insiders and hedge funds do not support a strong investment case.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 56.97, and moving averages are converging. The stock is trading near its pivot level of 3.299, with resistance at 3.501 and support at 3.097. There is no clear bullish or bearish trend.

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

The company reported a significant drop in net income (-29.23% YoY) and EPS (-76.94% YoY) in the latest quarter. No recent congress trading data or positive trading sentiment.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly to -3,429,124 (-29.23% YoY), and EPS fell to -1.01 (-76.94% YoY). Gross margin remains at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available.

1 Analyst Rating

Wall Street analysts forecast IMNN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.090

Low

Averages

High

Current: 3.090

Low

Averages

High

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

AI Analysis

2025-05-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-05-19

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.

Boral Capital

D. Boral

Buy

downgrade

$29 -> $17

2025-05-13

Reason

Boral Capital

D. Boral

Price Target

$29 -> $17

2025-05-13

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN

Unlock Now

IMNN Should I Buy

IMNN Should I Buy

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch